The Pharma Data

MARCH 15, 2022

For the Sarclisa ® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company Enable Injections , Inc. to advance the development of a subcutaneous delivery for Sarclisa ® with the goal of offering a unique patient-centric treatment experience. In the U.S.,

Life Science 52

Life Science Antibody Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 26, 2021

The safety profile of PDS in the clinical trial setting is well understood and will continue to be closely monitored. Roche has a robust phase III clinical development programme underway for PDS, including the Portal, Pagoda and Pavilion studies. m from baseline at Week 36.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

The Pharma Data

JANUARY 3, 2021

The Company’s pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration.

Production 52

Production Sales Development Licensing 52

Drug Discovery World

FEBRUARY 5, 2024

Dr Gen Li, Founder and President, Phesi “In 2024, we can expect immunotherapy trials to become a driving force for change in clinical development. In the past 10 years, immunotherapy trials have increased by 430%.

Research 116

Research Gene Sequencing Drug Delivery Systems Trials 116

Drug Discovery World

JANUARY 12, 2023

Here, Thomas reflects specifically on Anita Cooper’s prediction relating to the importance of clinical trials. . Following the launch of Protas, DDW spoke with Protas Chief Executive, Professor Sir Martin Landray, who echoed Cooper’s emphasis on the importance of clinical trial design.

Clinical Trials 97

Clinical Trials Clinical Trials Drugs Trials 97

The Pharma Data

APRIL 12, 2023

1 9 , 20 It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis. 2 6 About the Vabysmo ® ( faricimab ) clinical development programme Roche has a robust phase III clinical development programme for Vabysmo.

Antibody 40

Antibody In-Vitro Development Trials 40

The Pharma Data

DECEMBER 17, 2020

The trial remains on-track to complete enrollment of all 500 patients in the United States and Australia before the end of 2020, despite the worsening of the COVID-19 pandemic. In its Phase II clinical trial, TLC599 significantly reduced pain at and through every scheduled visit through six months.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Containment 40

Delveinsight

NOVEMBER 29, 2020

Therapies such as dexamethasone drug delivery system and vascular endothelial growth factor inhibitors have already pierced deeper into the market. Looking at its potential, the drug is also being watched out in diabetic macular edema in combination with intravitreal anti-VEGF drugs.

Marketing 52

Marketing Pharma Companies Drug Delivery Clinical Trials 52

Delveinsight

JULY 30, 2021

However, the Crohn’s disease market space experienced strides of research and developments imbibed with continuous innovation in terms of drug delivery platforms, MoAs, and RoAs with an end goal to minimize the numbers of patients experiencing no-response from the treatment.

Marketing 74

Marketing Drug Delivery Development Clinical Trials 74

The Pharma Data

JANUARY 17, 2021

The primary endpoint of this trial is to evaluate patients for complete histological clearance of the tumor cells within the treated BCC lesion with secondary endpoints, evaluating subjects for investigational product treatment related adverse events, as well as serious adverse events, and cutaneous skin reactions. Chief Medical Officer.

Gene Expression 52

Gene Expression Trials Production Development 52

The Pharma Data

DECEMBER 27, 2020

We remain confident that results from this trial will be positive given the outstanding results observed in our Phase II clinical trial.”. EXCELLENCE, a pivotal Phase III clinical trial to evaluate the efficacy and safety of both single and repeated doses of TLC599, is ongoing. SOUTH SAN FRANCISCO, Calif.

Trials 40

Trials Clinical Trials Clinical Trials Containment 40

Pharmaceutical Technology

MAY 31, 2023

Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Drug Delivery Systems 130

Drug Delivery Systems Drug Delivery Bacteria Drugs 130